First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding during Birth: Individual Treatment with Mononuclear Cells

Jensen, Arne; Hamelmann, Eckard

doi:10.1155/2016/1717426

Cited by 10 publications

(11 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the other perinatal and neonatal brain injuries have even less clinical data to support UCB transplantation. A recent study described a case report of UCB administered 4 years after a perinatal stroke that resulted in significant improvement in the subject's motor function (71). No clinical trials in perinatal stroke have been performed, however, and only one is currently ongoing, but has suspended recruitment.…”

Section: Status Of Clinical Administration Of Ucb For Pediatric Brainmentioning

confidence: 99%

From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain

et al. 2017

View full text Add to dashboard Cite

Stem cells are proving to be a promising therapy for a wide range of pediatric disorders, from neonatal hypoxic-ischemic encephalopathy to pediatric leukemia. Owing to their low immunogenicity and ease of availability, umbilical cord blood (UCB) progenitor cells are increasingly replacing fetal- and adult-derived cells in therapeutic settings. Multiple environmental and demographic factors affect the number and type of stem cells extracted from UCB, and these differences have been associated with disparities in outcomes after transplantation. To avoid variations in efficacy, as well as the potential adverse effects of stem cell transplantation, evaluation of the stem cell secretome is critical to identify key paracrine signals released by the stem cells that could be used to provide similar neuroprotective effects to stem cell transplantation. This article describes the cell types found in UCB and reviews the available literature surrounding the effects of collection timing and volume, maternal risk factors, delivery characteristics, and neonatal demographics on the cellular composition of UCB. In addition, the current findings regarding the stem cell secretome are discussed to identify factors that could be used to supplement or replace stem cell transplantation in pediatric neuroprotection.

show abstract

Section: Status Of Clinical Administration Of Ucb For Pediatric Brainmentioning

confidence: 99%

From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The first autologous transplant of UCB for pediatric ischemic stroke has recently been reported [146]. The work reports a child with right spastic hemiplegia who received 250 million UCB mononuclear cells at 5 years of age.…”

Section: Ucb In Clinical Trialsmentioning

confidence: 99%

Umbilical Cord Blood Cells for Perinatal Brain Injury: The Right Cells at the Right Time?

McDonald

Castillo‐Melendez

Penny

et al. 2017

Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine

View full text Add to dashboard Cite

Cerebral palsy (CP) is the most common cause of physical disability in children. CP currently has no cure and there are only few interventions to prevent the development of disability. There are four principal complications of pregnancy or birth that can damage the developing brain and lead to CP: preterm birth, fetal growth restriction, infection during pregnancy and severe hypoxia-ischemia at birth. Umbilical cord blood (UCB) cells are a very promising therapy for the treatment of CP. While UCB therapy for juveniles with CP is currently being assessed in clinical trials, very little is known about their mechanisms of action or which cells found in umbilical cord blood protect against and/ or repair brain injury. In this chapter, we first explore the complications that can lead to perinatal brain injury. We then discuss the different cell types found in UCB and the specific properties that make each of them individually attractive therapeutic candidates for treatment of perinatal brain injury. While UCB holds much promise as a therapy for CP, it is imperative that more research is conducted to understand how the different cell types found in UCB can protect against brain injury in order to design more effective and targeted therapies.

show abstract

“…In particular, early diagnosis is important in children with no aggravated perinatal history, as it allows an early start of therapy, especially with stem cells. Cord blood (CB) has been successfully used in CP in both auto- [2][3][4] and allogeneic [5,6] administrations. Animal studies have shown that the timing of stem cell administration is crucial for the effectiveness of CP therapy [7] and suggest that results may also be time-dependent in humans.…”

Section: Introductionmentioning

confidence: 99%

Autologous Cord Blood in Children with Cerebral Palsy: A Review

Boruczkowski

Pujal²,

Zdolińska-Malinowska

2019

IJMS

View full text Add to dashboard Cite

The aim of this narrative review is to report on the current knowledge regarding the clinical use of umbilical cord blood (CB) based on articles from PubMed and clinical trials registered on ClinicalTrials.gov. An increasing amount of evidence suggests that CB may be used for both early diagnostics and treatment of cerebral palsy. The acidity of CB and its biochemical parameters, including dozens of cytokines, growth factors, and other metabolites (such as amino acids, acylcarnitines, phosphatidylcholines, succinate, glycerol, 3-hydroxybutyrate, and O-phosphocholine) are predictors of future neurodevelopment. In addition, several clinical studies confirmed the safety and efficacy of CB administration in both autologous and allogeneic models, including a meta-analysis of five clinical trials involving a total of 328 participants. Currently, nine clinical trials assessing the use of autologous umbilical CB in children diagnosed with hypoxic-ischemic encephalopathy or cerebral palsy are in progress. The total population assessed in these trials exceeds 2500 patients.

show abstract

First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding during Birth: Individual Treatment with Mononuclear Cells

Cited by 10 publications

References 24 publications

From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain

From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain

Umbilical Cord Blood Cells for Perinatal Brain Injury: The Right Cells at the Right Time?

Autologous Cord Blood in Children with Cerebral Palsy: A Review

Contact Info

Product

Resources

About